Health·Le Monde·4h agoGlobal
Novo Nordisk, Eli Lilly Bet on Oral Weight-Loss Drugs
Oral versions to follow US success in global rollout
Positive1 min readImportance
AI Summary
Novo Nordisk and Eli Lilly are developing oral versions of their weight-loss drugs, following the success of their injectable products. After a successful US launch, they plan to expand distribution to multiple countries.
Keywords
oral weight-loss drugsNovo NordiskEli Lillypharmaceutical industryglobal expansion
